Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.60 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | CD4 | P01730 | 2/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14751054 | 0.89 | AKR1C3 (0.65) | AKR1C3ESR2KMT2AMEN1PKM | |
| SCHEMBL382362 | 0.89 | HDAC1 (0.54) | AKR1C3AKR1C1KMT2AMEN1PKM | |
| SCHEMBL2590065 | 0.84 | AKR1C3 (0.60) | AKR1C3ESR2OPRK1KMT2AMEN1 | |
| SCHEMBL5632587 | 0.83 | AKR1C3 (0.77) | AKR1C3AKR1C1ESR2KMT2AMEN1 | |
| SCHEMBL17786045 | 0.82 | AKR1C3 (0.58) | AKR1C3AKR1C1ESR2OPRK1 | |
| SCHEMBL13302259 | 0.81 | KMT2A (0.77) | AKR1C3KMT2AMEN1PKM | |
| SCHEMBL20389256 | 0.81 | AKR1C3 (0.60) | AKR1C3ESR2KMT2AMEN1PKM | |
| SCHEMBL20046985 | 0.81 | AKR1C3 (0.60) | AKR1C3AKR1C1ESR2KMT2AMEN1 | |
| SCHEMBL17786050 | 0.81 | AKR1C3 (0.73) | AKR1C3AKR1C1ESR2OPRK1 | |
| SCHEMBL26211248 | 0.81 | PKM (0.52) | AKR1C3ESR2KMT2AMEN1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173025-B1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED (GB) | 2007-02-06 | — | — | US | disclosed |
| EP-0880502-B1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ASTRAZENECA AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| US-20030207882-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2003-11-06 | — | — | US | disclosed |
| EP-0880502-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997028129-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1997-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207882-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | F2, SERPINC1, F11 | AKR1C3 582/4885AKR1C1 522/4885ESR2 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.